Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders

International Journal of Psychiatry in Medicine

Volumn 27, Issue 4, 1997, Pages 353-364

  Zimmer, Ben ^a   Kant, Ravi ^a   Zeiler, Debbie ^a   Brilmyer, Mary ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Antidepressive agents; Blood pressure; Serotonin norepinephrine uptake inhibitors; Venlafaxine

Indexed keywords

VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEAD INJURY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0031409206     PISSN: 00912174     EISSN: None     Source Type: Journal    
DOI: 10.2190/UDRD-99CB-T6KH-EDKP     Document Type: Article

References (16)

1. Montgomery SA. Venlafaxine: A new dimension in antidepressant pharmacotherapy. Journal of Clinical Psychiatry 1993;54:119-126.
2. Preskorn SH. Antidepressant drug selection: Criteria and options. Journal of Clinical Psychiatry 1994;55(suppl. A):6-22.
3. Nierenberg AA. The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? Journal of Clinical Psychiatry 1994; 55(9 suppl. A):55-59.
4. Product information: Effexor® (venlafaxine hydrochloride). Physicians' Desk Reference, 50th ed. Montvale, NJ: Medical Economics Co, 1996:2719-2723.
5. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, and ethyl cyclohexanol derivative. Biochemical Pharmacology 1986;35:4493-4497.
6. Yardley JP, Husbands GEM, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T, Fletcher H III, James MNG, Sielecki AR. 2-Phenyl-2-(1-hydroxycycloalkyl) ethylamine derivatives: Synthesis and antidepressant activity. Journal of Medical Chemistry 1990;33:2899-2905.
7. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research 1991;23:191-199.
8. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry 1995;56(10):450-458.
9. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin 1993;29:169-174.
10. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology 1991;11:233-236.
11. Feighner JP. Cardiovascular safety in depressed patients: Focus on venlafaxine. Journal of Clinical Psychiatry 1995;56:574-579.
12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994.
13. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacology Bulletin 1985;21:839-843.
14. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC V). Archives of Internal Medicine 1993; 153:154-183.
15. Amchin JD Ereshefsky L, Zarycranski WM. Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker. Presented at the 1996 annual meeting of the American Psychiatric Association; 1996 May 7; New York, NY.
16. Amchin JD, Zarycranski WM. Effect of venlafaxine on the pharmacokinetics of alprazolam. Presented at the 36th annual meeting of the New Clinical Drug Evaluation Unit of the National Institute of Mental Health; 1996 May 30; Boca Raton, FL.